Biomarker evaluation as the cardiotoxic evaluation index in the molecular target drug for breast cancer treatment

Not Applicable

• Conditions: HER2-positive breast cancer

• Registration Number: JPRN-UMIN000020690
• Lead Sponsor: Division of Breast Oncology,Cancer Institute Hospital of Japanese Foundation for Cancer Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-21
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

Not provided

Exclusion Criteria

1)The patient who withdrew an agreement 2)Examination participation of the patients is taken as inappropriate by the medical attendant

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The cardiotoxicity that was defined according to a standard of CREC(the Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity)